Cytoreductive surgery removes tumors that have spread throughout your abdominal cavity. It’s often combined with another procedure called hyperthermic intraperitoneal chemotherapy. You may need ...

“We have run out of chemotherapy options for this patient, so we have referred them for surgical evaluation to see if cytoreductive surgery and HIPEC is an option.” Clearly not all patients with PM ...

In over 400 women at first epithelial ovarian cancer recurrence, those who received HIPEC had a median OS of 54.3 months compared with 45.8 months for those who did not (HR 0.73, 95% CI 0.56-0.96, P=0 ...

Please provide your email address to receive an email when new articles are posted on . CHICAGO — In this video, Susana M. Campos, MD, MPH, discusses new data from the TRUST trial, which were ...

Declining cytoreductive surgery in advanced EOC is associated with significantly poorer survival outcomes compared to those who undergo the procedure. Sociodemographic factors, including race, age, ...

The association between residual tumor volume after primary cytoreduction and survival was less consistent in patients with low-grade serous ovarian carcinoma (LGSOC) compared with other histology ...

CHICAGO -- Upfront surgery for advanced ovarian cancer failed to improve overall survival (OS) versus interval debulking but did improve progression-free survival (PFS) for the first time in a phase ...

Deferred cytoreductive nephrectomy is associated with better survival compared with upfront surgery, including among fit patients receiving immunotherapy. Deferred cytoreductive nephrectomy (CN) may ...